Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PZ01 CAR-T for Relapsed/Refractory B-cell Malignancies
NCT03281551Phase 1Unknown
- Sponsor
- Pinze Lifetechnology Co. Ltd.
- Start
- Oct 2017
- Primary completion
- Sep 2020
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PZ01 CAR-T in B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma, sponsored by Pinze Lifetechnology Co. Ltd. Primary endpoint: Incidence of Treatment Related Adverse Events at 1 year. Status: unknown.
02
Drugs
PZ01 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT03281551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281551.